Characterization of blood donors with high haemoglobin concentration
|
|
- Jonas Bruce
- 5 years ago
- Views:
Transcription
1 STATE OF THE ART 2A-S05-02 ISBT Science Series (2013) 8, ISBT Science Series 2013 International Society of Blood Transfusion Characterization of blood donors with high haemoglobin concentration K. Magnussen, 1 H. Hasselbalch, 2 H. Ullum 1 & O. W. Bjerrum 2 1 Department of Clinical Immunology/Blood Centre, Copenhagen University Hospital, Copenhagen, Denmark 2 Department of Haematology, Copenhagen University Hospital, Copenhagen, Denmark The literature contains little on the prevalence and causes of high predonation haemoglobin levels among blood donors. This study aimed to characterize and develop an algorithm to manage would-be donors with polycythaemia. Between November 2009 and November 2011, we offered haematology consultations to blood donors with repeated haemoglobin concentration (Hb) above the WHO limit for polycythaemia vera (PV) (10.2 and 11.5 mm 16.5 and 18.5 g/dl for women and men, respectively). Investigation of such donors included Hb, haematocrit, mean cell volume, erythropoietin, ferritin, platelet count and leucocyte count, JAK2 V617F and JAK2 exon12 analysis, as well as other routine measurements. Among 46 such donors, 39 had a history of smoking, which contributes to erythrocytosis. Two had PV, five had severe hypertension, one of them because of renal artery stenosis, and two had diabetes mellitus. Thus, we found a high morbidity among such donors. Of the 36 others, 30 donated again before May 2012, at which time the Hb was significantly lower. We recommend JAK2 V617F and JAK2 exon12 screening and clinical investigation for donors with concurrently high Hb, high haematocrit and iron deficiency. We also recommend that they stop or cut down on smoking to reduce the risk of thrombosis in general. We disqualified 10 of the donors. Key words: blood donors, donor vigilance, haemoglobin, polycythaemia, transfusion medicine Introduction The literature contains little on the prevalence and causes of abnormally high haemoglobin levels in blood donors. In the year before this project, we encountered two donors with elevated Hb who were diagnosed with polycythaemia vera (PV). An excess of red blood cells, erythrocytosis, may be primary (PV), or secondary, caused by either congenital or acquired factors [1]. An elevated Hb or haematocrit (Hct) is often the observation indicating PV, and each individual blood donor is screened by at least one of these at each visit in the blood bank. A few studies before the JAK2 era [2 5] and after 2005 [6] reported on PV in blood donors. Besides, revised diagnostic criteria for PV are now based on WHO 2008, including the JAK2 status as a major criterion [7]. Correspondence: Karin Magnussen, Department of Clinical Immunology / Blood Centre, Copenhagen University Hospital, Copenhagen, Denmark karin.magnussen@regionh.dk Materials and methods The Capital Region of Denmark collects about blood donations per year and we have a stable cohort of approximately blood donors, including new donors every year. All donors, who are voluntary and unpaid, fill in a health questionnaire and have an interview before donation. With every donation, Hb is measured in venous blood from a presample bag attached to the blood bag (CPD SAG-M QUAD Optipure RC Fenwal). For inclusion in this study, the upper limit was chosen according to WHO recommendations for PV [7], that is, women with Hb above 102 mm (165 g dl) and men above 115 mm (185 g dl) on two succeeding donations were included. After the second high-hb test, all such persons were offered clinical investigations by a hospitalbased consultant in haematology. They were informed by telephone and letter, with assurance that participation was voluntary. Following consultation, blood samples 114
2 Blood donors with high haemoglobin 115 were drawn. Testing included Hb, Hct, mean cellular volume (MCV), erythropoietin (EPO), ferritin, transferrin and iron, leucocyte count, platelet count, JAK2 V617F [8] and JAK2 exon12 mutations [9]. Most donors were also screened for glucose, creatinine, thyroid-stimulating hormone, liver enzymes, etc. The total red cell mass was measured in a few donors. Selected donors had haemoglobin electrophoresis or endogenous erythroid colony assays. Vital parameters like blood pressure, pulse, oxygen saturation and clinical examination were routine. Statistics We used Student s t-test with a significance level of 5% for statistical analysis. Data are presented as means with range. Results The study period was 2 years from 23 November 2009 to 27 November Except for the Hb, the laboratory values were obtained at the first clinical examination, usually within 1 month of the donation; hence, Hct and ferritin may be lower than before the donation and EPO may be higher. In all, from donations, we offered further investigation to 48 donors (0021%, 35 women and 13 men). Only two declined, one because of concurrent investigations for diabetes mellitus, and the other because of a self-motivated reduction in smoking and coffee, which reduced her Hb from 103 mm (166 g/dl) to 95 mm (153 g/dl) at her next donation 6 months later. Accordingly, we included 46 donors in the study (33 women and 13 men) in addition to the two male donors diagnosed with PV in the year preceding this study. We included the latter two so as to illustrate in more detail the profile of patients with PV in this population of blood donors m 11.1 M JAK2 V617F(a) JAK2 V617F(b) Exon12 WildType WHO Hb Limit Dona ons before diagnosis of PV 18.5 g/dl Fig. 1 The development, in 4 donors, of hemoglobin concentrations, up to the diagnosis of PV. PV Of the 46 high-hb donors, one had JAK2 V617F positive PV. He was 59 years old and he had donated 99 times. His Hb was 116 mm (187 g/dl) with a mutation load of 37%. A 66-year-old man with Hb of 118 mm (190 g/dl) was JAK2 negative for both V617F and exon12, but positive in the endogenous erythroid colony assay and was diagnosed with PV. He had donated 103 times at the time of diagnosis. Of the two donors found in the preceding year to have PV, one was JAK2 V617F positive and one was JAK2 exon 12 positive (Fig. 1). Smoking About 85% of the high-hb donors were smokers, including one of those diagnosed with PV, whereas only 18% of our donors in general are smokers. Hypertension Five donors (11%; four women, one man) were found to have severe hypertension with a systolic pressure mmhg and diastolic mmhg respectively. One of the women with hypertension had concomitant diabetes mellitus, and another hypertensive woman was diagnosed and treated for renal artery stenosis. Diabetes mellitus Two women were diagnosed with diabetes mellitus, one with concomitant myxoedema and the other with hypertension as mentioned above. Normal variation One male donor was JAK2 wild type, and no secondary cause of erythrocytosis was found. This man had normal blood tests, including endogenous erythroid colony assay, and we concluded that the high Hb [120 mm (193 g/dl)] was a normal variation, and he has now returned as a regular blood donor. Other One woman with secondary erythrocytosis was excluded before the next donation because of an unspecified medication. One male donor dropped out after the initial investigations, which had revealed moderate hypertension and high homocysteine and cholesterol levels. One male donor 36 years of age from Pakistan with Hb 116 mm (185 g/dl) and noniron-deficient microcythaemia (MCV
3 116 K. Magnussen et al. Table 1 Basic data on the blood donors included Men with PV Men no PV Women no PV Significance n Age (55 66) (29 66) (27 64) Number of donations 115 (80 176) 69 (7 134) 42 (2 100) Plethoric n = 44 4 (100%) 6 (55%) 5 (15%) Hypermetabolic symptoms n = 44 2 (50%) 1 (9%) 0 Smokers 1 (25%) 9 (82%) 29 (88%) B-Hb mm 120 ( ) 119 ( ) 107 ( ) B-Hb g/dl B-Hct % n = 43 P-EPO IU n = 38 E-MCV fl n = 42 P-Ferritin µg/l n = 46 Geomean (range) B-Leucocyte count 10 9 /l n = 44 B-Platelet count 10 9 /l n = ( ) 54 (51 57) 34 (21 58) 79 (74 89) 19 (9 36) 114 (65 210) 280 ( ) 192 ( ) 51 (47 53) 88 (57 154) 92 (79 99) 91 (36 194) 86 (52 131) 223 ( ) 172 ( ) 46 (42 52) 94 (26 194) 92 (84 99) 37 (15 493) 88 (42 163) 280 ( ) P = 0037 P = 0002 P < 0000 P = 0008 Table 2 B-Hb on the donors who have donated again Male donors Female donors Donors donating again B-Hb when included mean (range) mm ( ) 192 g/dl ( ) mm ( ) 171 g/dl ( ) B-Hb at recent donation mean (range) 114 mm ( ) 184 g/dl ( ) 101 mm (89 108) 163 g/dl ( ) Significance P = 0008 P < 0000 In Table 1, data on the included donors are presented together with data on the two donors previously diagnosed with PV. Of the four donors with PV, two are JAK2 V617F positive, one is JAK2 exon 12 positive and one has no known JAK2 mutation. Of the 36 donors not deferred after the clinical investigation, 30 donated again. Table 2 shows that the Hb at the most recent donation was significantly lower than before the clinical investigation (P < 0000). This could be regression to the mean, but although we did not routinely ask the donors about changes in lifestyle, some told us they stopped or reduced smoking and consumption of coffee and tea. We therefore suggest that the reduction in Hb is indeed significant. 79fl) was tested with haemoglobin electrophoresis, which was normal. Smoking probably caused his high Hb, but we found no explanation of his mild microcythaemia. In all The clinical investigations identified 10 donors (217%) who were permanently deferred from blood donation, whereas 33 (717%) continued as regular donors and three (65%) chose not to donate again. Discussion We see far fewer high Hb values in blood donors than low, and our previous conclusion was that most of the high-hb donors were healthy and able to donate. However, we had found two male donors who were positive for JAK2 V617F and JAK2 exon 12 respectively. This and the need for an algorithm for donors with high Hb led us to investigate those with repeated high Hb level according to the WHO criteria [7], not only using JAK2 V617F and
4 Blood donors with high haemoglobin 117 JAK2 exon 12 tests but also a thorough clinical examination. Known causes of increased Hb level are PV and secondary polycythaemia because of such causes as low oxygen, lung disease, smoking, renal artery stenosis, increased secretion of EPO, hypertension, diabetes mellitus and the dehydration related to excessive intake of coffee, tea or alcohol as well as inadequate liquid intake. High Hb values are not uncommon in the general population, usually related to smoking or chronic lung disease. PV itself is a rare cause of elevated Hb [1, 10]. PV requires permanent disqualification from blood donation. The patient has to receive treatment to prevent serious devastating, thrombotic complications or hypermetabolic symptoms and microcirculatory disturbances, owing to hyper viscosity. Screening blood donors may now be simpler using the molecular markers [9] analysed on blood samples [1, 7, 8]. However, these analyses are expensive and not universally available and would not have found the donor that was only positive in the endogenous erythroid colony assay. This study therefore also aimed at describing if possible, simple tests to further identify blood donors with PV. PV is a rare disease, with epidemiologic data indicating an incidence of population in southern Sweden [11], and a prevalence of 02% positive for JAK2 V617F in the Copenhagen City Heart Study among participants aged [12]. In this study, only approximately 002% of donations had Hb above the WHO recommended level for investigating PV [7]. In 3 years, we found four donors with PV, of whom only two were JAK2 V617F positive, which does not suggest increased incidence in the donor population. Although an increased prevalence of PV exists in cigarette smokers [13], plethoric, non-smoking persons may be suspected of having PV. On the basis of this study, we recommend JAK2 617F and JAK2 exon12 analysis for iron-depleted donors suspected to have PV [7]. However, we do not recommend routine mutation analysis, because iron status plus high Hb and Hct are sufficient to identify those with a myeloproliferative neoplasm. We regularly monitor iron status in all our donors, following a standard protocol that was developed from a previous study [14]. Arterial hypertension may accompany erythrocytosis [10], and we identified five donors in this study with severe hypertension. In addition, hyperglycaemia was a contributing factor in two patients with type II diabetes mellitus. This group has a high prevalence of comorbidities (22%), and with increased hct, the risk of thromboembolic disease increases [10, 15]. In a few donors, we could not find a cause for secondary erythrocytosis [1]. We did endogenous erythroid colony assays in two [7], and haemoglobin electrophoresis [1] in another, to look for highoxygen haemoglobin variants [16]. In summary, PV is not more frequent among regular blood donors than in the general population. We recommend measuring blood pressure, iron-profile and possibly blood glucose in donors with repeatedly elevated Hb. Disclosure The authors have no conflicts of interests to declare. References 1 McMullin MF: The classification and diagnosis of erythrocytosis. Int J Lab Hematol 2008; 30: Merk K, Mattsson B, Mattsson A, et al.: The incidence of cancer among blood donors. Int J Epidemiol 1990; 19: Najean Y, Rain JD, Billotey C: Epidemiological data in polycythaemia vera: a study of 842 cases. Hematol Cell Ther 1998; 40:159 4 Randi ML, Rossi C, Barbone E, et al.: Myeloproliferative disease in patients with a history of multiple blood donations: a report of 8 cases. Haematologica 1994; 79: Zanella A, Silvani C, Banfi P, et al.:screening and evaluation of blood donors with upper-limit hematocrit levels. Transfusion 1987; 27: Tagariello G, Di Gaetano R, Sartori R, et al.: The JAK2V617F tyrosine kinase mutation in blood donors with upperlimit haematocrit levels. Blood Transfus 2009; 7:111 7 Swerdlow SH, Campo E, Harris N: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, International Agency for Research on Cancer, Lyon, France, A WHO publication, Larsen TS, Pallisgaard N, Moeller MB, et al.: Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow. Leukemia 2007; 22: Scott LM, Tong W, Levine RL, et al.: JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: Pearson TC: Apparent polycythaemia. Blood Rev 1991; 5: Kutti J, Ridell B: Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis. Pathol Biol (Paris) 2001; 49: Nielsen C, Birgens HS, Nordestgaard BG, et al.: The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Haematologica 2011; 96: Weinberg I, Borochowitz A, Krichevski S, et al.: Janus Kinase V617F mutation in cigarette smokers. Am J Hematol 2012; 87: Magnussen K, Bork N, Asmussen L: The effect of a standardized protocol for iron supplementation to blood donors
5 118 K. Magnussen et al. low in hemoglobin concentration. Transfusion 2008; 48: Messinezy M, Pearson TC: Apparent polycythaemia: diagnosis, pathogenesis and management. Eur J Haematol 1993; 51: Percy MJ, Butt NN, Crotty GM, et al.: Identification of high oxygen affinity hemoglobin variants in the investigation of patients with erythrocytosis. Haematologica 2009; 94:
Emerging diagnostic and risk stratification criteria
PV STATE OF MIND Polycythemia vera: Emerging diagnostic and risk stratification criteria Rami S. Komrokji, MD Moffitt Cancer Center, Tampa, Florida Disclosure These slides were developed by Incyte Corporation
More informationThe Internists Approach to Polycythemia and Implications of Uncontrolled Disease
The Internists Approach to Polycythemia and Implications of Uncontrolled Disease Mary Jo K. Voelpel, DO, FACOI, MA, CS Associate Clinical Professor MSU-COM Disclosures NONE Overview 1. Objectives 2. Case
More informationDepartment of Clinical Haematology
Diagnosis in Primary Care and referral pathway for patients with a raised haematocrit Why implement this pathway? A raised haemoglobin or haematocrit is a common finding and can be a reason for referral.
More informationCLINICAL CASE PRESENTATION
European Winter School of Internal Medicine 2015 Riga, Latvia, 26-30 January CLINICAL CASE PRESENTATION Vasiliy Chulkov South Ural State Medical University (Chelyabinsk, Russia) CHELYABINSK CLINICAL HISTORY
More informationHow to treat non-clonal polyglobulia: to bleed or not to bleed. Claire Harrison Guy s and St Thomas Hospitals London, UK
How to treat non-clonal polyglobulia: to bleed or not to bleed Claire Harrison Guy s and St Thomas Hospitals London, UK Disclosures Institutional research support: Novartis and Shire Pharmaceuticals Speaker:
More informationresearch paper Summary
research paper An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia Peter
More informationTechnical Bulletin No. 100
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 100 August 2, 2012 JAK2 AND MPL 515 MUTATIONAL ANALYSIS Contact: Dr. Jeffrey Wisotzkey, 717-851-1422 Technical Director, CPAL Jill A.
More informationرناد زكريا Dr. ahmad Dr. ahmad. P a g e 1
5 رناد زكريا Dr. ahmad Dr. ahmad P a g e 1 Before we start. -This sheet was written according to section 2 s record and reviewed according to section 1 s record by Ruba Hussien with all thanks and I referred
More informationCOEXISTENCE OF β-thalassemia AND POLYCYTHEMIA VERA: A CHICKEN-AND-EGG DEBATE?
COEXISTENCE OF β-thalassemia AND POLYCYTHEMIA VERA: A CHICKEN-AND-EGG DEBATE? M. DE SLOOVERE (1), L. HARLET (2), S. VAN STEENWEGHEN (3), E. MOREAU (1), D. DE SMET (1) (1) DEPARTMENT OF LABORATORY MEDICINE,
More informationDIAGNOSIS IN PRIMARY CARE AND REFERRAL PATHWAY FOR PATIENTS WITH A RAISED HAEMATOCRIT
DIAGNOSIS IN PRIMARY CARE AND REFERRAL PATHWAY FOR PATIENTS WITH A RAISED HAEMATOCRIT Document purpose A raised haemoglobin or haematocrit is a common finding and can be a reason for referral. This document
More informationMyeloproliferative Disorders in the Elderly: Clinical Presentation and Role of Bone Marrow Examination
Myeloproliferative Disorders in the Elderly: Clinical Presentation and Role of Bone Marrow Examination Arati V. Rao, M.D. Division of Medical Oncology and Geriatrics Duke University Medical Center Durham
More informationOpportunities for Optimal Testing in the Myeloproliferative Neoplasms. Curtis A. Hanson, MD
Opportunities for Optimal Testing in the Myeloproliferative Neoplasms Curtis A. Hanson, MD 2013 MFMER slide-1 DISCLOSURES: Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-2
More informationORIGINAL ARTICLE. The JAK2 V617F tyrosine kinase mutation in blood donors with upper-limit haematocrit levels
ORIGINAL ARTICLE The JAK2 V617F tyrosine kinase mutation in blood donors with upper-limit haematocrit levels Giuseppe Tagariello, Rosanna Di Gaetano, Roberto Sartori, Daniela Zanotto, Donata Belvini, Paolo
More informationPolycythemia Vera and Essential Thombocythemia A Single Institution Experience
INDIAN JOURNAL OF MEDICAL & PAEDIATRIC ONCOLOGY Vol. 29 No 4, 2008 7 Original Article-I Polycythemia Vera and Essential Thombocythemia A Single Institution Experience CECIL ROSS, NAVYA, VANAMALA AND KARUNA
More informationTemplate for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms
Template for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms Version: MPNBiomarkers 1.0.0.2 Protocol Posting Date: June 2017 This biomarker template is NOT required for accreditation
More informationWHO Update to Myeloproliferative Neoplasms
WHO Update to Myeloproliferative Neoplasms Archana M Agarwal, MD, Associate Professor of Pathology University of Utah Department of Pathology/ARUP Laboratories Myeloproliferative Neoplasms The categories
More informationWelcome to Master Class for Oncologists. Session 3: 9:15 AM - 10:00 AM
Welcome to Master Class for Oncologists Session 3: 9:15 AM - 10:00 AM Miami, FL December 18, 2009 Myeloproliferative Neoplasms: Bringing Order to Complexity and Achieving Optimal Outcomes Speaker: Andrew
More information[COMPREHENSIVE GENETIC ASSAY PANEL ON
2014 SN GENELAB AND RESEARCH CENTER DR. SALIL VANIAWALA, PH.D [COMPREHENSIVE GENETIC ASSAY PANEL ON MYELOPROLIFERATIVE NEOPLASMS] SN Genelab presents one of the most comprehensive genetic assay panel for
More informationLatest updates in Myeloproliferative Neoplasms. Elizabeth Hexner, MD, MSTR
Latest updates in Myeloproliferative Neoplasms Elizabeth Hexner, MD, MSTR Disclosures Nothing to disclose Agenda/Goals Treatment goals in PV Indications for cytoreduction in patients polycythemia vera
More informationChronic Myeloproliferative Disorders
1 Chronic Myeloproliferative Disorders 15th 9 April2015 Polycythemia vera Essential thrombocythemia Idiopathic primary myelofibrosis 2 Learning objectives To appreciate types of polycythaemia (erythrocytosis)
More informationPolycythemia Vera and other Myeloproliferative Neoplasms. A.Mousavi
Polycythemia Vera and other Myeloproliferative Neoplasms A.Mousavi Chronic MPNs Multipotent hematopoietic progenitor cell is origin. Overproduction of one or more formed element of blood cells without
More informationDisclosure BCR/ABL1-Negative Classical Myeloproliferative Neoplasms
Disclosure BCR/ABL1-Negative Classical Myeloproliferative Neoplasms Sonam Prakash declares affiliation with Incyte Corporation: Advisor for Hematopathology Publications Steering Committee Sonam Prakash,
More informationHFE mutations in idiopathic erythrocytosis
HFE mutations in idiopathic erythrocytosis Biagetti, G., Catherwood, M., Robson, N., Bertozzi, I., Cosi, E., McMullin, M. F., & Randi, M. L. (2017). HFE mutations in idiopathic erythrocytosis. British
More informationWhy do patients with polycythemia vera clot? Kinsey McCormick Hematology Fellows conference August 10, 2012
Why do patients with polycythemia vera clot? Kinsey McCormick Hematology Fellows conference August 10, 2012 Outline Case presentation Overview of PV Disease course Mechanisms of thrombosis Case Presentation
More informationMYELOPROLIFERATIVE NEOPLASMS
9 : 2 MYELOPROLIFERATIVE NEOPLASMS Introduction William Dameshek in 1951 introduced the term Myeloproliferative disorders (MPD). This included polycythemia vera (PV), essential thrombocythemia (ET), primary
More informationPractice Patterns in the Diagnosis and Treatment of Polycythemia Vera in the Post JAK2 V617F Discovery Era
1238 Original Research Practice Patterns in the Diagnosis and Treatment of Polycythemia Vera in the Post JAK2 V617F Discovery Era Elizabeth M. Kander, MD a ; Alison R. Moliterno, MD b ; Alfred Rademaker,
More informationFactors affecting oxygen dissociation curve
P a g e 1 Factors affecting oxygen dissociation curve As you know, hemoglobin contains 4 heme molecules that bind 4 oxygen molecules (8 atoms). These 4 heme molecules, however, do not bind oxygen all at
More informationBy Angela Gascoigne Haematology CNS Chesterfield Royal Hospital
By Angela Gascoigne Haematology CNS Chesterfield Royal Hospital Myeloproliferative Neoplasms Essential Thrombocythaemia Polycythaemia Vera Myelofibrosis Essential Thrombocythaemia (ET) Chronic condition
More informationIs the recommended hematocrit target in polycythemia vera evidence based? Tiziano BARBUI, MD Ospedali Riuniti, Bergamo, Italy
Is the recommended hematocrit target in polycythemia vera evidence based? Tiziano BARBUI, MD Ospedali Riuniti, Bergamo, Italy We have generated a transgenic mouse line that reaches a hematocrit concentration
More informationHow to monitor MPN patients
How to monitor MPN patients MPN carries significant burden and risk Transformation to MF or AML 1 Neurological complications 2 MPN-associated general symptoms (eg, pruritus, fatigue) 3 Microvascular symptoms
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationJAK2 Inhibitors for Myeloproliferative Diseases
JAK2 Inhibitors for Myeloproliferative Diseases Srdan (Serge) Verstovsek M.D., Ph.D. Associate Professor Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA Myeloproliferative
More informationSupplementary information. Supplementary figure 1. Flow chart of study design
Supplementary information Supplementary figure 1. Flow chart of study design Supplementary Figure 2. Quantile-quantile plot of stage 1 results QQ plot of the observed -log10 P-values (y axis) versus the
More informationClinical Perspective The Hematologist s View
SPLANCHNIC VEIN THROMBOSIS. TYPICAL OR ATYPICAL MPN? Giovanni Barosi Unit of Clinical Epidemiology/Center ofr the Study of Myelofibrosis. IRCCS Policlinico S. Matteo Foundation, Pavia Lisbon, 4-5 May 2012
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: October 15, 2018 Related Policies: None JAK2, MPL and CALR Testing for Myeloproliferative Neoplasms Description Somatic (acquired) genetic variants in JAK2, MPL,
More informationGuidelines for diagnosis and management of adult myeloproliferative neoplasms (PV, ET, PMF and HES)
Guidelines for diagnosis and management of adult myeloproliferative neoplasms (PV, ET, PMF and HES) Author: Dr N Butt, Consultant Haematologist On behalf of the Haematology CNG Written: July 2010 Reviewed:
More informationAbstract. Hematopathology / Early Prepolycythemic Phase of PV
Hematopathology / Early Prepolycythemic Phase of PV The Significance of Bone Marrow Biopsy and JAK2 V617F Mutation in the Differential Diagnosis Between the Early Prepolycythemic Phase of Polycythemia
More informationMyelodysplastic syndrome (MDS) & Myeloproliferative neoplasms
Myelodysplastic syndrome (MDS) & Myeloproliferative neoplasms Myelodysplastic syndrome (MDS) A multipotent stem cell that can differentiate into any of the myeloid lineage cells (RBCs, granulocytes, megakaryocytes)
More informationAnemia. A case-based approach. David B. Sykes, MD, PhD Hematology, MGH Cancer Center June 8, 2017
Anemia A case-based approach David B. Sykes, MD, PhD Hematology, MGH Cancer Center June 8, 2017 Recognizing trends Learning Objectives MCV, RDW, Ferritin, LDH, Reticulocytes Managing complex patients 1.
More informationA. ILEA 1* A. M. VLADAREANU 2 E. NICULESCU-MIZIL 3
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 9 (58) No. 1-2016 THE SIMULTANEOUS OCCURRENCE OF THE BCR-ABL TRANSLOCATION AND THE Jak2V617F MUTATION. DETECTION AND DYNAMICS
More informationCLINICAL POLICY DEPARTMENT: Medical Management DOCUMENT NAME: JakafiTM REFERENCE NUMBER: NH.PHAR.98
PAGE: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationRESEARCH ARTICLE. Abstract. Introduction
RESEARCH ARTICLE Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms Roongrudee Singdong 1, Teerapong Siriboonpiputtana
More informationTherapeutic Phlebotomy
REVIEW Therapeutic Phlebotomy Abba Zubair, M.D., Ph.D. Indications Therapeutic phlebotomy is indicated as an integral component of the treatment of several medical conditions. It is the cheapest and most
More informationHighest rates of thrombosis = age > 70, history of thrombosis, active disease (> 6 phlebotomies/yr) [2]
Polycythemia Vera Treatment Policy Prepared by Dr. Jeannie Callum Updated May 2003 Introduction PV is a chronic, clonal, myeloproliferative disorder, classically associated with an increase in red cell
More informationCharacterization of MPL-mutated myeloid neoplasms: a review of 224 MPL+ cases
Article Characterization of MPL-mutated myeloid neoplasms: a review of 224 MPL+ cases Keming Lin 1,*, Gang Xu 1, Jie-Gen Jiang 1, Mayuko Imai 1, Zhao Wu 1, Paris Petersen 1, Kim Janatpour 1, and Bashar
More informationMasked polycythaemia vera: presenting features, response to treatment and. clinical outcomes. Running title: masked polycythaemia vera.
Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes Running title: masked polycythaemia vera Alberto Alvarez-Larrán 1, Anna Angona 1, Agueda Ancochea 1, Francesc
More informationFocus on aggressive polycythemia vera
Focus on aggressive polycythemia vera Jerry L. Spivak, MD Professor of Medicine and Oncology Director, the Johns Hopkins Center for the Chronic Myeloproliferative Disorders Johns Hopkins University School
More informationIndividualized dosing for Jakafi (ruxolitinib)
Individualized dosing for Jakafi (ruxolitinib) Indications and Usage Polycythemia vera Jakafi is indicated for treatment of patients with polycythemia vera who have had an inadequate response to or are
More informationAnemia in the elderly. Nattiya Teawtrakul MD., PhD
Anemia in the elderly Nattiya Teawtrakul MD., PhD Contents Definition of anemia in the elderly The impact of anemia in the elderly Etiology of anemia in the elderly Management of anemia in the elderly
More informationBrief Communication Diagnostic Hematology
Brief Communication Diagnostic Hematology Ann Lab Med 2015;35:233-237 http://dx.doi.org/10.3343/alm.2015.35.2.233 ISSN 2234-3806 eissn 2234-3814 Incidence, Clinical Features, and Prognostic Impact of CALR
More informationTemplate for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms
Template for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms Template web posting date: December 2014 Authors Todd W. Kelley, MD, FCAP University of Utah and ARUP Laboratories,
More informationChapter 22: Hematological Complications
Chapter 22: Hematological Complications 22.1: Perform a complete blood count at least (Not Graded): daily for 7 days, or until hospital discharge, whichever is earlier; two to three times per week for
More informationTreatment of polycythemia vera with recombinant interferon alpha (rifnα)
Treatment of polycythemia vera with recombinant interferon alpha (rifnα) Richard T. Silver, MD Professor of Medicine Weill Cornell Medical College New York, New York Outline of Lecture What are interferons?
More informationThe average adult produces red cells every
MYELOPROLIFERATIVE DISORDERS Idiopathic erythrocytosis: a disappearing entity Mary Frances McMullin 1 1 Centre for Cancer Research and Cell Biology, Queen s University, Belfast, N. Ireland. Erythrocytosis
More informationMyeloproliferative Neoplasms and Treatment Overview
Myeloproliferative Neoplasms and Treatment Overview George Nesr Clinical Research Fellow in Haematology Haematology Department Imperial College Healthcare NHS Trust Overview Historical Background Pathogenesis
More information27027 Tourney Road Valencia, CA 91355 800 421 7110 www.specialtylabs.com Test Updates November 26, 2008 Dear Colleague: We are pleased to announce the availability of two new assays for an expanded evaluation
More informationTranexamic acid and Iron in Haematology. Andy King-Venables Transfusion Practitioner Hinchingbrooke Hospital
Tranexamic acid and Iron in Haematology Andy King-Venables Transfusion Practitioner Hinchingbrooke Hospital Why consider an alternative? Can t we just give blood? Why consider an alternative? Can t we
More informationAbsence of CALR Mutations in Idiopathic Erythrocytosis Patients with Low Serum Erythropoietin Levels
Absence of CALR Mutations in Idiopathic Erythrocytosis Patients with Low Serum Erythropoietin Levels Catherwood, M. A., Graham, A., Cuthbert, R. J. G., Garrec, C., Gardie, B., Girodon, F.,... McMullin,
More informationMYELOPROLIFARATIVE NEOPLASMS. Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin).
MYELOPROLIFARATIVE NEOPLASMS Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin). These are a group of chronic conditions characterised by clonal proliferation of marrow precursor cells. PRV, essential thrombocyathaemia,
More informationRecognizing and treating the patient with high-risk polycythemia vera. Kim-Hien Dao, DO, PhD Oregon Health & Science University Portland, Oregon
Recognizing and treating the patient with high-risk polycythemia vera Kim-Hien Dao, DO, PhD Oregon Health & Science University Portland, Oregon Disclosure These slides were developed by Incyte Corporation
More informationSerum soluble transferrin receptor in hypochromic microcytic anaemia
O r i g i n a l A r t i c l e Singapore Med Med J 2006; J 2006; 47(2) 47(2) : 138 : 1 Serum soluble transferrin receptor in hypochromic microcytic anaemia Jayaranee S, Sthaneshwar P ABSTRACT Introduction:
More informationErythropoiesis Stimulating Agents (ESAs): Epoetin Alfa * DIALYSIS *
Erythropoiesis Stimulating Agents (ESAs): Epoetin Alfa * DIALYSIS * DESCRIPTION Erythropoietin is a glycoprotein produced in the kidneys responsible for the stimulation of red blood cell production. Epoetin
More informationCONGENITAL ERYTHROCYTOSIS. Mary Frances McMullin
CONGENITAL ERYTHROCYTOSIS Mary Frances McMullin m.mcmullin@qub.ac.uk Disclosures No relevant disclosures Learning outcomes Describe the mechanism of red cell production following signalling from the erythropoietin
More information74y old Female with chronic elevation of Platelet count. August 18, 2005 Faizi Ali, MD Hematopathology Fellow
74y old Female with chronic elevation of Platelet count August 18, 2005 Faizi Ali, MD Hematopathology Fellow Clinical History Patient is a 74y old otherwise healthy Caucasian female with no major complaint
More informationJAK2 V617F and the evolving paradigm of polycythemia vera
VOLUME 45 ㆍ NUMBER 2 ㆍ June 2010 THE KOREAN JOURNAL OF HEMATOLOGY REVIEW ARTICLE JAK2 V617F and the evolving paradigm of polycythemia vera Robert T. Means, Jr. Department of Internal Medicine and Markey
More informationRED CELL DISTRIBUTION WIDTH
RED CELL DISTRIBUTION WIDTH A NEW MARKER OF EXERCISE INTOLERANCE IN PATIENTS WITH CHRONIC HEART FAILURE Emeline Van Craenenbroeck, Paul Beckers, Nadine Possemiers, Christiaan Vrints, Viviane Conraads Cardiology
More informationAlister Jones Patient Blood Management Practitioner NHS Blood and Transplant
Alister Jones Patient Blood Management Practitioner NHS Blood and Transplant All medical RCC transfusions (but only 1 in 3 haematology or oncology cases) in 3 x one week periods Medical specialties include:
More informationThe treatment of polycythaemia vera: an update in the JAK2 era
Intern Emerg Med (2007) 2:13 18 DOI 10.1007/s11739-007-0003-4 IM REVIEW G. Finazzi T. Barbui The treatment of polycythaemia vera: an update in the JAK2 era Received: 31 August 2006 / Accepted in original
More informationRelated Policies None
Medical Policy MP 2.04.60 BCBSA Ref. Policy: 2.04.60 Last Review: 07/25/2018 Effective Date: 07/25/2018 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational
More informationWHAT IS YOUR DIAGNOSIS?
WHAT IS YOUR DIAGNOSIS? A 12 year old, female neutered domestic shorthaired cat was presented to the R(D)SVS Feline Clinic with a 6 week history of polydipsia and polyuria, which was not quantified. The
More informationORIGINAL ARTICLE. A Tefferi 1, TL Lasho 1, J Huang 1, C Finke 1, RA Mesa 1,CYLi 2,WWu 3, CA Hanson 2 and A Pardanani 1
(28) 22, 756 76 & 28 Nature Publishing Group All rights reserved 887-6924/8 $3. www.nature.com/leu ORIGINAL ARTICLE, compared to either a higher allele burden or unmutated status, is associated with inferior
More informationEuropean Focus on Myeloproliferative Diseases and Myelodysplastic Syndromes A critical reappraisal of anagrelide in the management of ET
European Focus on Myeloproliferative Diseases and Myelodysplastic Syndromes 2012 Clinical i l Aspects of Polycythemia and Essential Thrombocythemia A critical reappraisal of anagrelide in the management
More informationPolycthemia Vera (Rubra)
Polycthemia Vera (Rubra) Polycthemia Vera (Rubra) Increased red cells Clonal Myeloid lineages also increased 2-13 cases per million Mean age: 60 years Sites of Involvement Bone marrow Peripheral blood
More informationBONE MARROW PERIPHERAL BLOOD Erythrocyte
None Disclaimer Objectives Define anemia Classify anemia according to pathogenesis & clinical significance Understand Red cell indices Relate the red cell indices with type of anemia Interpret CBC to approach
More informationESM Table 2 Data extraction form and key data from included studies
ESM Table 2 Data extraction form and key data from included studies Author, year and title Behan, 2006 [21] Cessation of menstruation improves the correlation of FPG to hemoglobin A 1c in Caucasian women
More informationErythrocytosis due to presumed polycythemia vera
A SELF-TEST ON A CLINICAL CASE The patient is presumed to have polycythemia vera but does she? IM BOARD REVIEW EDUCATIONAL OBJECTIVE: Readers will pursue a step-by-step approach to evaluating patients
More informationA prospective, multicenter European Registry for newly diagnosed patients with Myelodysplastic Syndromes of IPSS low and intermediate-1 subtypes.
Protocol Synopsis Study Title A prospective, multicenter European Registry for newly diagnosed patients with Myelodysplastic Syndromes of IPSS low and intermediate-1 subtypes. Short Title European MDS
More informationUtilizing Sysmex RET He to Evaluate Anemia in Cancer Patients
Utilizing Sysmex RET He to Evaluate Anemia in Cancer Patients Ellinor I. Peerschke, Ph.D., F.A.H.A. Vice Chair, Laboratory Medicine Chief, Hematology & Coagulation Laboratory Services Memorial Sloan Kettering
More informationDisclosures. Myeloproliferative Neoplasms: A Case-Based Approach. Objectives. Myeloproliferative Neoplasms. Myeloproliferative Neoplasms
Myeloproliferative Neoplasms: A Case-Based Approach Disclosures No conflicts of interests regarding the topic being presented Adam M. Miller, MD PGY-4 Resident Physician Department of Pathology and Laboratory
More informationUnderstanding Your Blood Work Results
Understanding Your Blood Work Results Carlos Besses, MD, hd Hematology Department Hospital del Mar - IMIM, Barcelona Carlos Besses Disclosures Novartis Honorarium Speaker Shire Honorarium Speaker Galena
More informationComplete molecular remission in a polycythaemia vera patient 12 years after discontinuation of interferon-alpha
Complete molecular remission in a polycythaemia vera patient years after discontinuation of interferon-alpha Philip T. Murphy, Suzanne Mcpherson, Stephen E. Langabeer To cite this version: Philip T. Murphy,
More informationAnaemia & Cancer. John de Vos Consultant Haematologist RSCH
Anaemia & Cancer John de Vos Consultant Haematologist RSCH overview Definitions & setting the scene Causes Consequences Biology Treatment Personal approach Patient Clinical team Anaemia - Definition :
More informationReproducibility of Histologic Classification in Nonfibrotic Myeloproliferative Neoplasia
Hematopathology / Morphologic Features in MPN Reproducibility of Histologic Classification in Nonfibrotic Myeloproliferative Neoplasia Suzanne M. Koopmans, MD, 1 Freek J. Bot, MD, PhD, 1,2 King H. Lam,
More informationUpdate on hemoglobin and ferritin with data from the Danish Blood Donor Study
The Danish Blood Donor Study Update on hemoglobin and ferritin with data from the Danish Blood Donor Study Henrik Ullum Copenhagen University Hospital Topics Iron depletion in blood donors Clinical consequences
More informationJAK2 V617F Mutation in Patients With Catastrophic Intra-abdominal Thromboses
Coagulation and Transfusion Medicine / JAK2 V617F IN ABDOMINAL THROMBOSIS JAK2 V617F Mutation in Patients With Catastrophic Intra-abdominal Thromboses Christine McMahon, MD, 1,2 Kareem Abu-Elmagd, MD,
More informationDepartment of Hematology, Sakarya University Training and Research Hospital, Sakarya, Turkey.
Original Article Hematology Medical Journal of Islamic World Academy of Sciences doi: 10.5505/ias.2018.90093 2018;26(3): 59-64 Retrospective analysis of patients with chronic myeloproliferative neoplasms:
More informationDr Marina Karakantza Consultant Haematologist, NHSBT
Dr Marina Karakantza Consultant Haematologist, NHSBT Overview Definition of transfusion thresholds Mechanisms of adaptation to anaemia How RBC transfusion affect adaptation mechanisms to anaemia Triggers
More informationTania Paarman Western Province Blood Transfusion Service (WPBTS), Cape Town, South Africa
THERAPEUTIC PHLEBOTOMY AND BLOOD DONATION IN PATIENTS WITH HEREDITARY HAEMOCHROMATOSIS AND ERYTHROCYTOSIS: A 15 YEAR REVIEW IN THE WESTERN CAPE REGION OF SOUTH AFRICA Tania Paarman Western Province Blood
More informationMPL W515L K mutation
MPL W515L K mutation BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
More informationMeasuring Thrombopoietin
Measuring Thrombopoietin - 2012 A New Tool for Hematologists? Mervyn A. Sahud, M.D. A.B.I.M.-Hem. Medical Director, Coagulation Department Quest Diagnostics Nichols Institute San Juan Capistrano, CA Disclosure
More informationTransfusion-Related Acute Lung Injury (TRALI) and Strategies for Prevention. Khalid Abdulla Sharif, MD, MRCP (UK)*
Bahrain Medical Bulletin, Vol. 29, No.4, December 2007 Transfusion-Related Acute Lung Injury (TRALI) and Strategies for Prevention Khalid Abdulla Sharif, MD, MRCP (UK)* Background: Transfusion-Related
More informationTHE KENYA POLYTECHNIC UNIVERSITY COLLEGE
THE KENYA POLYTECHNIC UNIVERSITY COLLEGE SCHOOL OF HEALTH SCIENCES AND TECHNOLOGY DEPARTMENT OF BIOMEDICAL LABORATORY SCIENCES AND TECHNOLOGY DIPLOMA IN MEDICAL LABORATORY SCIENCE END OF YEAR 1 EXAMINATION
More informationNovel drugs in MPNs: Histone-Deacetylase Inhibitors
Novel drugs in MPNs: HistoneDeacetylase Inhibitors 1st Annual Florence MPN Meeting April 16, 2011 Guido Finazzi Chronic Myeloproliferative Neoplasm Unit Division of Hematology Ospedali Riuniti di Bergamo,
More informationReport dei gruppi di lavoro >> [ Disordini mieloproliferativi cronici ]
Report dei gruppi di lavoro >> [ Disordini mieloproliferativi cronici ] Relatore: G. BAROSI 27-28 ottobre 2008 Borgo S. Luigi Monteriggioni (Siena) Disordini mieloproliferativi cronici - Copyright FSE
More informationSignificant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study
Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study François Girodon, 1,2 Gilles Bonicelli, 1 Céline Schaeffer,
More informationVenesection Nursing Guidelines
Venesection Nursing Guidelines Rationale Patients requiring venesection on the Day Treatment Unit (DTU) fall into 3 main categories; patients diagnosed with: Polycythemia Rubra Vera Haemachromatosis Transfusion
More informationTaking The Fear Out of Abnormal CBC s Problems of Production, Destruction or loss
Taking The Fear Out of Abnormal CBC s Problems of Production, Destruction or loss Joanne Eddington, MN, FNP, AOCN Providence Oncology and Hematology Care Clinic - Eastside Blood Cell Abnormalities Abnormalities
More informationIron depletion in frequently donating whole blood donors. B. Mayer, H. Radtke
Iron depletion in frequently donating whole blood donors B. Mayer, H. Radtke Iron: relevance oxygen-transporting and storage proteins hemoglobin and myoglobin iron-containing centers in many enzymes mitochondrial
More informationMethylation status of SOCS1 and SOCS3 in BCR-ABL negative and. JAK2V617F negative chronic myeloproliferative disorders.
Methylation status of SOCS1 and SOCS3 in BCR-ABL negative and JAK2V617F negative chronic myeloproliferative disorders. To the Editor BCR-ABL negative Chronic Myeloproliferative Disorders (s) are a heterogeneous
More information